NCT05658601View on ClinicalTrials.gov

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

CompletedOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

July 14, 2023

Primary Completion Date

July 3, 2025

Study Completion Date

July 3, 2025

Conditions
Multiple Sclerosis, Relapsing-Remitting
Trial Locations (1)

86077

Local Institution - 0001, Isernia

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05658601 - A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | Biotech Hunter | Biotech Hunter